Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile IDH1 R132X
Therapy Olaparib
Indication/Tumor Type chondrosarcoma
Response Type no benefit

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
IDH1 R132X chondrosarcoma no benefit Olaparib Phase II Actionable In a Phase II trial, Lynparza (Olaparib) treatment did not demonstrate activity in patients with advanced solid tumors (n=26), including chondrosarcoma (n=14), harboring IDH1 mutations (R132C, n=12) with no objective responses, a median progression-free survival of 2 months, and a median overall survival of 7.5 months (J Clin Oncol 2025 43: 16_suppl, 3087; NCT03212274). detail...
PubMed Id Reference Title Details
A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors. Full reference...